A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Patients with moderate to severe pain caused by medical conditions or surgery, who require IV
opioid therapy may be enrolled in this open label safety study. Patients will be treated with
TRV130 by IV bolus, PCA (patient-controlled analgesia) administration, or both, as determined
by the investigator, for a duration not to exceed 14 days.